Randomized, phase Ib/II study of M6620 1 avelumab 1 carboplatin vs standard care (sc) in patients (pts) with platinum-sensitive poly (ADP-ribose) polymerase inhibitor-(PARPi)-resistant ovarian cancer

Category Primary study
ConferenceAnnals of Oncology
Year 2019
This article has no abstract
Epistemonikos ID: 727e5190ce8dcd743696d3e65d7ce0f360d25336
First added on: Feb 11, 2025